NEC
19.3.2021 03:02:08 CET | Business Wire | Press release
NEC Corporation (NEC; TOKYO: 6701) and its subsidiary OCC Corporation announced today that they have completed full qualification of subsea repeaters and optical cable containing up to 24 fiber pairs (FPs) (48 fibers). This is a 50% improvement in fiber count over the 16 fiber pair systems generally available today. This development allows cable owners worldwide to construct subsea telecom cables with superior traffic capacity while reducing the cost per bit of the wet plant. This approach is fully in line with SDM (Space Division Multiplexing) system architectures. NEC’s 24 FP solution not only provides more flexibility to operate in the subsea fiber pair market, it also enables better connectivity in high-density subsea branches.
NEC achieved this milestone with minor modifications to its proven repeater and cable designs. Keeping NEC’s quadruple pump redundancy in the repeater (established more than 10 years ago) and maintaining OCC’s outstanding cabling performance has resulted in cabled attenuations lower than 0.150dB/km. Low attenuation is critical to achieve large spectral efficiency as well as lower power consumption.
“As global demands for capacity and FP flexibility continue to soar, NEC is committed to helping our customers to build up their subsea networks with large spectral efficiency, lower power consumption and large-scale subsea connectivity,” said Yoshihisa Inada, Deputy General Manager and Head of Subsea Technology Development at NEC’s Submarine Network Division. “We continue to evaluate multiple technical options to further increase capacity and reduce the cost/bit of the networks.”
OCC’s 24 fiber pair cable can be manufactured using a wide range of existing optical fibers, according to the needs of each new cable system. Each fiber can be visually identified using a field-proven combination of ring marking and conventional fiber coloring, first introduced in 2013. Furthermore, in OCC cable, the fiber’s transmission performance is completely unaffected, either by the fiber marking or cabling processes.
“We have concluded that the use of our fibers in OCC’s 24 pair cable results in a cabled attenuation matching the nominal value. We are confident that our ultra-low-loss fibers can contribute to achieve large capacity, high spectral efficiency and low power consumption in transoceanic networks,” said Dr. Masashi Onishi, General Manager at Optical Fiber and Cable division of Sumitomo Electric Industries Ltd.
“To support growing bandwidth, next generation subsea systems will offer Petabit-scale transmission. To achieve the required performance, cabling processes must capture the advantaged optical attenuation and large effective area of our ultra-low-loss fibers. OCC’s cabling process for 24 fiber pairs works with our high quality fiber to meet the challenge,” said Dr. Bernhard Deutsch, VP & GM, Optical Fiber & Cable, Corning Incorporated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318006059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
